Subjects meeting all the following criteria will be included in the study: <br/ > <br/ >1.Male & Female patients with age ranging from 40 to 65 years (both inclusive)& female (non-pregnant, non-lactating, post-menopausal, surgically sterilized or practicing a reliable method of birth control during the duration of study) <br/ > <br/ >2.Clinically stable condition for at least 6 months before enrollment. <br/ > <br/ >3.Confirmed diagnosis of at least moderate COVID-19 symptoms demonstrated by: <br/ >a.Positivity in RT-PCR 2019-nCov test on respiratory tract (nasopharyngeal / oropharyngeal) specimens. <br/ >b.Presence of clinical features of dyspnea and/or hypoxia, fever, cough, including SpO2 < 94% (range 90-94%) on room air, Respiratory Rate > 24 and < 30 breaths per minute. <br/ > <br/ >4.Significant COVID-19 symptoms, and judged by the treating doctor to be at high risk of progression to severe category due to presence of any of the following: <br/ >a.Having at least one of the high-risk criteria, i.e, obesity (BMI â?¥ 30 kg/m2), diabetes mellitus, uncontrolled hypertension (diastolic blood pressure > 90 mm Hg systolic blood pressure â?¥150 mm Hg), known respiratory disease (including asthma or chronic obstructive pulmonary disease), known heart failure, known coronary disease, <br/ >b.Demonstrating signs of cardiac injury due to Elevated troponin level, <br/ > <br/ >5.Patients who require hospitalization for control of disease at the time of study entry. <br/ > <br/ >6.Within 7 days from symptom onset or within 48 hours of laboratory diagnosis of SARS- CoV2. <br/ > <br/ >7.Able to take oral tablets and agreeing not to participate in any other study for duration of participation in this study. <br/ > <br/ >8.Willing to sign voluntary informed consent for participation in the study and willing to adhere to all protocol procedures. In case the subject is unable to provide informed consent than the same should be obtained from legally acceptable representative (LAR). <br/ >

Subjects meeting all the following criteria will be included in the study: <br/ > <br/ >1.Male & Female patients with age ranging from 40 to 65 years (both inclusive)& female (non-pregnant, non-lactating, post-menopausal, surgically sterilized or practicing a reliable method of birth control during the duration of study) <br/ > <br/ >2.Clinically stable condition for at least 6 months before enrollment. <br/ > <br/ >3.Confirmed diagnosis of at least moderate COVID-19 symptoms demonstrated by: <br/ >a.Positivity in RT-PCR 2019-nCov test on respiratory tract (nasopharyngeal / oropharyngeal) specimens. <br/ >b.Presence of clinical features of dyspnea and/or hypoxia, fever, cough, including SpO2 < 94% (range 90-94%) on room air, Respiratory Rate > 24 and < 30 breaths per minute. <br/ > <br/ >4.Significant COVID-19 symptoms, and judged by the treating doctor to be at high risk of progression to severe category due to presence of any of the following: <br/ >a.Having at least one of the high-risk criteria, i.e, obesity (BMI â?¥ 30 kg/m2), diabetes mellitus, uncontrolled hypertension (diastolic blood pressure > 90 mm Hg systolic blood pressure â?¥150 mm Hg), known respiratory disease (including asthma or chronic obstructive pulmonary disease), known heart failure, known coronary disease, <br/ >b.Demonstrating signs of cardiac injury due to Elevated troponin level, <br/ > <br/ >5.Patients who require hospitalization for control of disease at the time of study entry. <br/ > <br/ >6.Within 7 days from symptom onset or within 48 hours of laboratory diagnosis of SARS- CoV2. <br/ > <br/ >7.Able to take oral tablets and agreeing not to participate in any other study for duration of participation in this study. <br/ > <br/ >8.Willing to sign voluntary informed consent for participation in the study and willing to adhere to all protocol procedures. In case the subject is unable to provide informed consent than the same should be obtained from legally acceptable representative (LAR). <br/ >

Subjects meeting all the following criteria will be included in the study: <br/ > <br/ >1.Male & Female patients with age ranging from 40 to 65 years (both inclusive)& female (non-pregnant, non-lactating, post-menopausal, surgically sterilized or practicing a reliable method of birth control during the duration of study) <br/ > <br/ >2.Clinically stable condition for at least 6 months before enrollment. <br/ > <br/ >3.Confirmed diagnosis of at least moderate COVID-19 symptoms demonstrated by: <br/ >a.Positivity in RT-PCR 2019-nCov test on respiratory tract (nasopharyngeal / oropharyngeal) specimens. <br/ >b.Presence of clinical features of dyspnea and/or hypoxia, fever, cough, including SpO2 < 94% (range 90-94%) on room air, Respiratory Rate > 24 and < 30 breaths per minute. <br/ > <br/ >4.Significant COVID-19 symptoms, and judged by the treating doctor to be at high risk of progression to severe category due to presence of any of the following: <br/ >a.Having at least one of the high-risk criteria, i.e, obesity (BMI â?¥ 30 kg/m2), diabetes mellitus, uncontrolled hypertension (diastolic blood pressure > 90 mm Hg systolic blood pressure â?¥150 mm Hg), known respiratory disease (including asthma or chronic obstructive pulmonary disease), known heart failure, known coronary disease, <br/ >b.Demonstrating signs of cardiac injury due to Elevated troponin level, <br/ > <br/ >5.Patients who require hospitalization for control of disease at the time of study entry. <br/ > <br/ >6.Within 7 days from symptom onset or within 48 hours of laboratory diagnosis of SARS- CoV2. <br/ > <br/ >7.Able to take oral tablets and agreeing not to participate in any other study for duration of participation in this study. <br/ > <br/ >8.Willing to sign voluntary informed consent for participation in the study and willing to adhere to all protocol procedures. In case the subject is unable to provide informed consent than the same should be obtained from legally acceptable representative (LAR). <br/ >

Subjects meeting all the following criteria will be included in the study: <br/ > <br/ >1.Male & Female patients with age ranging from 40 to 65 years (both inclusive)& female (non-pregnant, non-lactating, post-menopausal, surgically sterilized or practicing a reliable method of birth control during the duration of study) <br/ > <br/ >2.Clinically stable condition for at least 6 months before enrollment. <br/ > <br/ >3.Confirmed diagnosis of at least moderate COVID-19 symptoms demonstrated by: <br/ >a.Positivity in RT-PCR 2019-nCov test on respiratory tract (nasopharyngeal / oropharyngeal) specimens. <br/ >b.Presence of clinical features of dyspnea and/or hypoxia, fever, cough, including SpO2 < 94% (range 90-94%) on room air, Respiratory Rate > 24 and < 30 breaths per minute. <br/ > <br/ >4.Significant COVID-19 symptoms, and judged by the treating doctor to be at high risk of progression to severe category due to presence of any of the following: <br/ >a.Having at least one of the high-risk criteria, i.e, obesity (BMI â?¥ 30 kg/m2), diabetes mellitus, uncontrolled hypertension (diastolic blood pressure > 90 mm Hg systolic blood pressure â?¥150 mm Hg), known respiratory disease (including asthma or chronic obstructive pulmonary disease), known heart failure, known coronary disease, <br/ >b.Demonstrating signs of cardiac injury due to Elevated troponin level, <br/ > <br/ >5.Patients who require hospitalization for control of disease at the time of study entry. <br/ > <br/ >6.Within 7 days from symptom onset or within 48 hours of laboratory diagnosis of SARS- CoV2. <br/ > <br/ >7.Able to take oral tablets and agreeing not to participate in any other study for duration of participation in this study. <br/ > <br/ >8.Willing to sign voluntary informed consent for participation in the study and willing to adhere to all protocol procedures. In case the subject is unable to provide informed consent than the same should be obtained from legally acceptable representative (LAR). <br/ >